1 2 aim

Project Hercules will receive Eurordis Company Award for Patient Engagement

In November 2017 Duchenne UK launched Project HERCULES to support access to new treatments for Duchenne Muscular Dystrophy (DMD). Today, Eurordis announced they will award Duchenne UK and the companies involved in this project for their collaboration with patients with an EURORDIS Black Pearl Award in the category Company Award for Patient Engagement 2019. 

About the project

Hercules is a unique international multi-stakeholder collaborative project that is working to develop tools and evidence to support Health Technology Assessments and reimbursement decisions for new treatments for Duchenne Muscular Dystrophy (DMD). It brings together leading pharmaceutical companies, academics, patient organisations and advisers to develop and build a better evidence base for DMD.

Project HERCULES aims to develop a common disease level evidence base containing all the elements required for Health Technology Assessment that companies can adapt for their products. This should lead to a broader evidence base that better captures the impact of DMD on patients, families and society, improved economic modelling, lower costs and management time and better use of patient input.

Click here to find out more about the Hercules project


EURORDIS Black Pearl Awards

The EURORDIS Black Pearl Awards recognise the outstanding achievements and ground-breaking work of those committed to improving the lives of people living with a rare disease. The Awards are presented to patient advocates, patient organisations, policy makers, scientists, companies and media at a unique annual event held every year in February to mark the occasion of Rare Disease Day.

For more information, please contact the project team at [email protected] or visit hercules.duchenneuk.org